z-logo
open-access-imgOpen Access
Survival in Patients With Severe Aortic Regurgitation and Severe Left Ventricular Dysfunction Is Improved by Aortic Valve Replacement
Author(s) -
Ashvin Kamath,
Padmini Varadarajan,
Rami Turk,
Unnati Sampat,
Reena Patel,
Sumit Khandhar,
Ramdas G. Pai
Publication year - 2009
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.108.839787
Subject(s) - medicine , aortic valve replacement , cardiology , ejection fraction , hazard ratio , regurgitation (circulation) , retrospective cohort study , cohort , aortic valve , propensity score matching , heart failure , stenosis , confidence interval
Background— Aortic valve replacement (AVR) in patients with severe aortic regurgitation (AR) and left ventricular (LV) dysfunction entails a higher surgical risk. Though it may improve symptoms and LV size, it is not known whether it translates into a survival benefit.Methods and Results— This retrospective cohort study included patients screened from our echocardiographic database between 1993 and 2007 for patients with severe AR and LV ejection fraction (EF) ≤35%. Charts reviews were conducted for clinical, pharmacological, and surgical information. Mortality data were obtained from the social security death index and analyzed as a function of AVR adjusted for the propensity score. Of the 785 patients with severe AR, 166 patients had severe LV dysfunction defined as an EF ≤35%: 69% of these were men, age 65±16 years, and LV EF was 23±8%. Kaplan–Meier analysis revealed that performance of AVR (n=53) was associated with a better survival (P =0.001). Adjusted for the propensity score, AVR was associated with a significantly lower mortality hazard (HR 0.59, CI 0.42 to 0.98,P =0.04).Conclusions— There is a clear reluctance to offer AVR in a large number of patients with severe AR associated with LV dysfunction. However, the performance of AVR in these patients is associated with a mortality benefit supporting the current ACC/AHA guidelines.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom